Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Study supports use of 'soft' IVF treatment

05 February 2007

By Zulehkha Waheed

Appeared in BioNews 397

Women trying to have a baby using standard IVF techniques are spending money on unnecessary drugs that have harmful side-effects and which could be compromising their health, according to the authors of a new report published in the Lancet medical journal.

In standard IVF, two embryos are usually implanted, after stimulating the woman's ovaries with large doses of hormones, which can cause side-effects such as hot flushes, night sweats, insomnia, reduced libido and depression. This treatment can sometimes trigger ovarian hyper-stimulation syndrome, and also increases the risk of multiple births, which carry a higher risk of complications for mother and baby and can induce premature birth.

A report published in 1999 described an approach that uses reduced drug doses, has a shortened treatment period, and involves implanting just one embryo at a time (so-called 'single embryo transfer', or SET). This method is known as 'soft IVF' and uses hormone antagonists which bypass the side-effects that are triggered by conventional IVF drugs. In the latest study, Bert Fauser's team at the University Medical Centre in Utrecht compared 'soft' and 'standard' IVF treatment in 404 patients.

Their results show that replacing one embryo in the womb at a time, and freezing another for use in a second, has the same live birth rate (44 per cent) over one year as standard IVF. They also noted that this approach reduces the risk of ovarian hyper-stimulation, and that the chances of having twins is dramatically cut to 1 in 200 births from 1 in 8 births in standard IVF. They also claim that the soft version was cheaper overall by €2400 per pregnancy.

The authors believe that soft IVF will revolutionise conventional IVF as it will benefit patients and clinics by encouraging repeat attempts at IVF, 'Our findings should encourage more widespread use of mild ovarian stimulation and single embryo transfer in clinical practice', the researchers said. They continued: 'However adoption of our mild IVF treatment strategy would need to be supported by counselling both patients and healthcare providers to redefine IVF success and explain the risks associated with multiple pregnancies'.

It is thought that getting SET accepted as routine practice will be challenging in the UK. Professor Bill Ledger, an IVF specialist at the University of Sheffield, acknowledged the ever increasing gap between demand and supply on NHS resources and reflects that it just is not feasible for the NHS to follow recommendations by the National Institute for Health and Clinical Excellence (NICE) set out in its 2004 report, which recommended providing all couples with three free cycles of IVF treatment. He continued by saying, 'Some patients want to complete the procedure as quickly as possible and see twins as the most desirable outcome. While 75 per cent of IVF treatment in the UK continues to be paid for by the patients themselves, many couples will opt for double embryo transfer because it is much less costly'.

Professor Ledger also explained that it would be difficult to get private IVF clinics to adopt new guidelines because the Human Fertilisation and Embryology Authority (HFEA) rates their position in the 'league table' according to their success per cycle, and as mild IVF may take more cycles, this could reflect badly upon them. A spokesperson from the HFEA said: 'We are about to launch a consultation about trying to minimise multiple births because they are the single biggest risk involved in IVF'. The authority is due to announce its new policy in the autumn.

SOURCES & REFERENCES
The Guardian | 02 March 2007
 
Medical News Today | 02 March 2007
 
Treatments for IVF are needlessly aggressive and risky, says report
The Independent | 02 March 2007
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

28 April 2008 - by Dr Rebecca Robey 
A new study presented to the International Society for Mild Approaches in Assisted Reproduction (ISMAAR) at their Second World Congress held in London earlier this month raises the possibility of a new 'lunch hour' IVF treatment. The Invocell capsule, manufactured by the Massachusetts-based company, BioXcell, is designed...
14 April 2008 - by Dr Rachael Panizzo 
By Rachael Dobson: A milder form of IVF treatment that has fewer side effects and is less expensive does not reduce the chances of a successful pregnancy, according to a new study. Research led by Dr Marinus Eijkemans, at Utrecht University Medical Centre in the Netherlands, reported that the milder...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation